208 related articles for article (PubMed ID: 16315127)
41. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
[TBL] [Abstract][Full Text] [Related]
42. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
[TBL] [Abstract][Full Text] [Related]
43. Validation of self-reported history of colorectal cancer screening.
Khoja S; McGregor SE; Hilsden RJ
Can Fam Physician; 2007 Jul; 53(7):1192-7. PubMed ID: 17872816
[TBL] [Abstract][Full Text] [Related]
44. Colon cancer screening: which non-invasive filter tests?
Pox C
Dig Dis; 2011; 29 Suppl 1():56-9. PubMed ID: 22104755
[TBL] [Abstract][Full Text] [Related]
45. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
Haug U; Hundt S; Brenner H
Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
[TBL] [Abstract][Full Text] [Related]
46. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
[TBL] [Abstract][Full Text] [Related]
47. Colorectal cancer screening behavior in women attending screening mammography: longitudinal trends and predictors.
Carlos RC; Fendrick AM; Abrahamse PH; Dong Q; Patterson SK; Bernstein SJ
Womens Health Issues; 2005; 15(6):249-57. PubMed ID: 16325138
[TBL] [Abstract][Full Text] [Related]
48. Colorectal cancer test use--Maryland, 2002-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
[TBL] [Abstract][Full Text] [Related]
49. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
Inadomi JM
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
[TBL] [Abstract][Full Text] [Related]
50. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
[TBL] [Abstract][Full Text] [Related]
51. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
Shastri YM; Povse N; Schröder O; Stein J
Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
[No Abstract] [Full Text] [Related]
52. Screening for colorectal cancer.
Hakama M; Hoff G; Kronborg O; Påhlman L
Acta Oncol; 2005; 44(5):425-39. PubMed ID: 16118076
[TBL] [Abstract][Full Text] [Related]
53. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
54. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas.
Morikawa T; Kato J; Yamaji Y; Wada R; Mitsushima T; Sakaguchi K; Shiratori Y
Am J Gastroenterol; 2007 Oct; 102(10):2259-64. PubMed ID: 17617203
[TBL] [Abstract][Full Text] [Related]
55. Screening colonoscopy and fecal occult blood testing practice patterns: a population-based survey of gastroenterologists.
Rossi F; Sosa JA; Aslanian HR
J Clin Gastroenterol; 2008; 42(10):1089-94. PubMed ID: 18936643
[TBL] [Abstract][Full Text] [Related]
56. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
[TBL] [Abstract][Full Text] [Related]
57. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
58. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
[TBL] [Abstract][Full Text] [Related]
59. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
[TBL] [Abstract][Full Text] [Related]
60. Validation of self-reported colorectal cancer screening behavior from a mixed-mode survey of veterans.
Partin MR; Grill J; Noorbaloochi S; Powell AA; Burgess DJ; Vernon SW; Halek K; Griffin JM; van Ryn M; Fisher DA
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):768-76. PubMed ID: 18381474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
